Considerations regarding an updated meta-analysis of the optimal duration ofoxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer
Favorite
Share
More Options
2

Open in WPS to view all 2 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
